Clinical Trial Update: Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab [Phase 4]

View source ↗

Summary

Clinical trial exploring hypersensitivity to CGRP as a predictive biomarker for migraine prevention with erenumab in a Phase 4 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• erenumab (erenumab)

Snippet

Sponsor: Danish Headache Center | Conditions: Migraine | Phase 4 | Status: UNKNOWN